The marine-derived HIF-1α inhibitor, Yardenone 2, reduces prostate cancer cell proliferation by targeting HIF-1 target genes
Open Access
- 8 July 2024
- journal article
- research article
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 29 (1) , 1-19
Abstract
Background: Prostate cancer (PCa) ranks as the second most prevalent cancer in men, with advanced stages posing significant treatment challenges. Given its solid tumor nature, PCa is highly susceptible to hypoxia, a condition associated with resistance to radiation and chemotherapy, metastasis, and unfavorable patient outcomes. Hypoxia-inducible factors (HIFs) play a pivotal role in cancer cell adaptation to hypoxic environments, contributing to treatment resistance. Consequently, inhibitors targeting HIFs hold promise for cancer therapy. Methods: In this study, we aimed to characterize novel HIF-1α inhibitors including Sodwanones A (1), B (2), C (3), G (4) and Yardenone 2 (5) isolated from marine sponges belonging to the Axinella genus. Our investigation evaluated the impact of these compounds on various aspects of HIF-1α regulation, including stabilization, nuclear localization, expression of HIF-1 target genes (while sparing HIF-2 target genes), cellular metabolism, as well as cell proliferation and viability in prostate cells under hypoxic conditions. Results: Our findings revealed that among the compounds tested, Yardenone 2 exhibited notable effects in hypoxia: it destabilized HIF-1α at the protein level, decreased its nuclear localization, selectively altered the expression of HIF-1 target genes, and restrained cell proliferation in aggressive PC3 prostate cancer cells as well as in an MSK-PCa3 patient-derived organoid line. Moreover, it affected the morphology of these organoid. Yardenone 2 was also compared to Docetaxel, a specific microtubule inhibitor and a drug used in the treatment of prostate cancer. The comparison between the two compounds revealed notable differences, such as a lack of specificity to hypoxic cells of Docetaxel. Conclusion: These results mark the first demonstration that Yardenone 2 functions as a cytostatic-like inhibitor impacting microtubules, specifically targeting hypoxic cancer cells. This discovery suggests a promising avenue for novel therapeutic interventions in prostate cancer.Keywords
Funding Information
- Ligue Contre le Cancer
- China Scholarship Council
This publication has 30 references indexed in Scilit:
- Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathwayNeoplasia, 2022
- Immune-modulating and anti-inflammatory marine compounds against cancerSeminars in Cancer Biology, 2022
- HIF Inhibitors: Status of Current Clinical DevelopmentCurrent Oncology Reports, 2019
- Hypoxia-Inducible Factors: Master Regulators of Cancer ProgressionTrends in Cancer, 2016
- Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses CysteineCell, 2016
- Organoid Cultures Derived from Patients with Advanced Prostate CancerCell, 2014
- Microtubule targeting agents: from biophysics to proteomicsCellular and Molecular Life Sciences, 2010
- HIF-1: master and commander of the hypoxic worldBiochemical Pharmacology, 2004
- Yardenone A and B: New Cytotoxic Triterpenes from the Indian Ocean Sponge Axinella cf. bidderiJournal of Natural Products, 2002
- Sodwanones A-C, three new triterpenoids from a marine spongeTetrahedron Letters, 1993